IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity
Clostridioides difficile infection (CDI) recurs in 1 of 5 patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2+ ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI.
Authors
- Farha Naz (ORCID: https://orcid.org/0000-0003-0647-4613)
- Audrey C. Brown (ORCID: https://orcid.org/0000-0001-5572-0396)
- Girija Ramakrishnan (ORCID: https://orcid.org/0000-0002-9543-3583)
- Isaura Rigo
- Gregory R. Madden (ORCID: https://orcid.org/0000-0002-5951-3156)
- William A. Petri (ORCID: https://orcid.org/0000-0002-7268-1218)
- Rachel Boone (ORCID: https://orcid.org/0000-0001-9355-4202)
- Mary K. Young (ORCID: https://orcid.org/0000-0002-4754-1440)
- Md. Jashim Uddin (ORCID: https://orcid.org/0000-0002-2466-7198)
- David Tyus
- C. Fleming (ORCID: https://orcid.org/0009-0005-3905-5847)
- Nicholas Hagspiel
Institutions
- Office of Infectious Diseases (US)
- University of Virginia (US)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1172/jci184659
- Citations
- 4
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- National Institutes of Health